-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下：利安德巴塞尔工业公司（LYB）公布第一季度运营每股收益为0.49美元，高于去年同期的0.33美元，超出市场预期0.21美元。此前六个季度中有四个季度未达预期。营收为72亿美元，低于市场预期2%，同比下降6%。公司完成了一项战略里程碑，出售了四项欧洲资产，推进了其投资组合转型计划，预计将提高利润率、降低成本，并增强LYB的抗风险能力。管理层对第二季度业绩给出了积极的预期，计划最大限度地提高北美O&P（运营和生产）的开工率，将欧洲O&P的开工率提高到80%，并将I&D（集成和拆卸）的开工率维持在75%。然而，尽管盈利有所回升，但由于营运资本增加以及满足全球需求增长，第一季度的运营现金流显著恶化至负2.69亿美元。鉴于持续存在的结构性产能过剩和持续的地缘政治动荡，我们认为预期改善的可持续性仍存在不确定性。
Related Articles
Research
Research Alert: CFRA Retains Hold View On Shares Of Incyte Corporation
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 earnings, we keep our target at $102, 11.8x our projected 2027 EPS forecast, below its five-year historical forward P/E average of 17.0x. We adjust our 2026 EPS estimate to $7.83 from $7.94 and our 2027 EPS view to $8.64 from $8.36. INCY reported a solid start to 2026, beating expectations on both revenue and earnings, led by robust, double-digit growth across its commercial portfolio. We think the company is going through a strategic transition beyond its cornerstone product, Jakafi, toward a diversified portfolio in hematology, oncology, and immunology, supported by a maturing late-stage pipeline and key management appointments. INCY announced the appointments of Suketu Upadhyay (the current CFO of ZBH) as its new CFO, effective May 4, and a new Head of U.S. Commercial, Mohamed Issa. While we see some execution risks ahead, we believe INCY could be at an inflection point with four new product launches in the next year and the advancement of the 10 Phase 3 studies while filling key leadership roles.
$INCY
Australia
GSK's Linerixibat Gets UK Nod for Itch Linked to Biliary Disease
GSK's (GSK) Linerixibat, to be marketed as Lynavoy, has been approved by the UK's Medicines and Healthcare products Regulatory Agency for the treatment of itching in adults with primary biliary cholangitis, the agency said Friday.The oral therapy aims to reduce bile acid buildup linked to the rare liver disease, which can cause persistent itching, the agency said.The approval was supported by phase 3 data showing Linerixibat significantly reduced itching and improved sleep disruption compared with placebo, it added.Shares of GSK were down 1.2% in Friday trading.Price: $52.01, Change: $-0.30, Percent Change: -0.57%
$GSK
International
ISM US Manufacturing Index Indicates Steady Expansion in April
The Institute for Supply Management's US manufacturing index was unchanged in April from the 52.7 reading in March, below the expectations for a 53.2 reading in a survey compiled by Bloomberg as of 7:40 am ET.There were gains in the readings for new orders and prices, but declines in production, employment and order backlogs.Other regional manufacturing sector readings have been generally positive, with exception of the Dallas and Chicago regions.The monthly national manufacturing reading from the Institute for Supply Management is reported as a headline index, with readings above 50 indicating expansion and those below 50 indicating contraction. Component indexes measure new orders, production, employment, and prices.An increase in the index further above 50 is considered a sign of a strong US manufacturing sector, generally a positive for manufacturing industry stocks. However, if that strength comes with rising input prices due to shortages, that could be a negative for stocks as well as bonds.